Cencora revises 2026 outlook, shares underpinned by buyback and analyst support

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 10:33.

Cencora Inc. (US15135B1017) enters the weekend with a refreshed fiscal 2026 earnings outlook and a sizable buyback in place, while its shares trade on the NYSE under the ticker COR. The company’s updated guidance and capital return plans are now being digested by Wall Street analysts, including Bank of America and other houses that cover this large-cap healthcare distributor.

Updated guidance and buyback program

Cencora’s board reaffirmed and fine-tuned its fiscal 2026 adjusted earnings per share guidance in May, setting a range around 17.65 to 17.90 dollars. This guidance update followed second-quarter revenue of roughly 78.4 billion dollars, a 3.8 percent increase year on year, supported by a 13 percent rise in International Healthcare Solutions revenue as reported in recent commentary.

Alongside the outlook, Cencora approved a share repurchase authorization of about 2.0 billion dollars, which allows the company to buy back up to roughly 3.9 percent of its outstanding shares in the open market. The buyback decision, taken in late May, adds a clear capital-return component to the investment case and signals confidence in the long-term trajectory of the business.

Analyst views and NYSE trading context

Analyst coverage of Cencora centers on its role in the pharmaceutical distribution chain and the visibility of earnings under the revised guidance. According to recent data, around twelve analysts rate the stock as Buy and three as Hold, resulting in a moderate buy consensus with an average target near 367.75 dollars per share.

Bank of America recently raised its price objective on Cencora to 285 dollars from 280 dollars and maintained a neutral stance, reflecting a more cautious view compared with the broader consensus. On June 26, 2026, Cencora shares closed at approximately 286.97 dollars on the NYSE, with extended trading later showing a marginal move to about 286.12 dollars, indicating relatively muted short-term volatility around the updated guidance and buyback.

The business behind the stock

Cencora operates as a global pharmaceutical distribution and healthcare solutions company, supplying prescription drugs and related services to pharmacies, hospitals and healthcare providers in North America and internationally. Its International Healthcare Solutions segment, which posted a double-digit revenue increase in the latest reported quarter, focuses on specialty logistics and services that support cross-border drug access and clinical trials.

The group’s scale in drug wholesaling and specialty distribution gives it a central role in the supply chain between manufacturers such as large pharmaceutical firms and end dispensers, with fee-based services and volume-driven margins shaping earnings quality. This business mix is a key factor behind the relatively stable cash flows that underpin both its guidance and the decision to commit capital to the buyback program.

Where the shares trade today

As of the last verified close on 2026-06-26, 15:59 Eastern Time, Cencora shares (US15135B1017) traded on the NYSE at approximately 286.97 dollars, with a reported 52-week range between about 244.82 and 377.54 dollars. The company’s market capitalization at that price level sits in the large-cap bracket among U.S. healthcare distributors, adding to its relevance in sector indices and institutional portfolios.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on publicly available sources believed to be reliable as of the stated dates, but may change without notice.